Xintela’s oncology subsidiary, Targinta AB, and MSK’s Therapeutics Accelerator to develop integrin α10β1 antibody therapeutic in patients with aggressive sarcoma
Evy Lundgren-Åkerlund, CEO Xintela and Targinta, said, “The collaboration with MSK gives us a fantastic opportunity to clinically develop Targinta’s antibodies, targeting integrin α10β1, together with a leading global cancer center. In preclinical cancer models, we have shown that our lead candidates TARG9, an ADC (Antibody-drug conjugate), and TARG10, a function-blocking antibody, effectively inhibit tumor growth and metastasis of aggressive cancers such as triple-negative breast cancer, glioblastoma and sarcoma. Published results from Dr. Samuel Singer’s research group at MSK (Okada et al, 2016) complement our results and further validate integrin α10β1 as a unique cancer target. This collaboration will now create the opportunity to bring Targinta’s new targeted cancer therapy to patients for the first time. This is a breakthrough for Xintela’s oncology program and a great milestone for our wholly owned subsidiary Targinta.
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a